company background image

Biotika BSSE:1BSL01AE Stock Report

Last Price


Market Cap







10 Aug, 2022


Company Financials
1BSL01AE fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance1/6
Financial Health6/6

1BSL01AE Stock Overview

Biotika a.s. operates as a pharmaceutical manufacturing company in Slovakia and internationally.

Biotika Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Biotika
Historical stock prices
Current Share Price€38.60
52 Week High€42.00
52 Week Low€37.20
1 Month Change0%
3 Month Change-1.03%
1 Year Change-1.03%
3 Year Change33.10%
5 Year Change10.29%
Change since IPO-95.08%

Recent News & Updates

Nov 30
Should You Buy Biotika a.s. (BSSE:1BSL01AE) For Its Dividend?

Should You Buy Biotika a.s. (BSSE:1BSL01AE) For Its Dividend?

Is Biotika a.s. (BSSE:1BSL01AE) a good dividend stock? How can we tell? Dividend paying companies with growing...

Shareholder Returns

1BSL01AESK PharmaceuticalsSK Market

Return vs Industry: 1BSL01AE underperformed the SK Pharmaceuticals industry which returned 2.9% over the past year.

Return vs Market: 1BSL01AE underperformed the SK Market which returned 3.6% over the past year.

Price Volatility

Is 1BSL01AE's price volatile compared to industry and market?
1BSL01AE volatility
1BSL01AE Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement5.8%
Market Average Movement5.5%
10% most volatile stocks in SK Market10.4%
10% least volatile stocks in SK Market2.9%

Stable Share Price: Insufficient data to determine 1BSL01AE's volatility over the past 3 months.

Volatility Over Time: Insufficient data to determine 1BSL01AE's volatility change over the past year.

About the Company


Biotika a.s. operates as a pharmaceutical manufacturing company in Slovakia and internationally. The company offers active pharmaceutical ingredients (API), including phenoxymethylpenicillin potassium, phenoxymethylpenicillin potassium granulated, phenoxymethylpenicillin calcium, and polymyxin B sulfate (non-sterile) substances; and pharmaceutical preparations for the human and veterinary applications. It is also involved in the contract manufacture of APIs comprising Gramicidin S hydrochlorid (non-sterile) and L-CYSTINE substances; and antibiotics.

Biotika Fundamentals Summary

How do Biotika's earnings and revenue compare to its market cap?
1BSL01AE fundamental statistics
Market Cap€37.95m
Earnings (TTM)€405.71k
Revenue (TTM)€8.91m


P/E Ratio


P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
1BSL01AE income statement (TTM)
Cost of Revenue€16.09m
Gross Profit-€7.19m
Other Expenses-€7.59m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date


Earnings per share (EPS)0.41
Gross Margin-80.67%
Net Profit Margin4.55%
Debt/Equity Ratio0.002%

How did 1BSL01AE perform over the long term?

See historical performance and comparison



Current Dividend Yield


Payout Ratio
We’ve recently updated our valuation analysis.


Is 1BSL01AE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 1/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1BSL01AE?

Other financial metrics that can be useful for relative valuation.

1BSL01AE key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue4x
Enterprise Value/EBITDA17x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does 1BSL01AE's PE Ratio compare to its peers?

1BSL01AE PE Ratio vs Peers
The above table shows the PE ratio for 1BSL01AE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average50.1x
524075 Albert David
ACTIVEFINE Active Fine Chemicals
532649 Nectar Lifesciences
1BSL01AE Biotika

Price-To-Earnings vs Peers: 1BSL01AE is expensive based on its Price-To-Earnings Ratio (93.5x) compared to the peer average (50.1x).

Price to Earnings Ratio vs Industry

How does 1BSL01AE's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

Price-To-Earnings vs Industry: 1BSL01AE is expensive based on its Price-To-Earnings Ratio (93.5x) compared to the European Pharmaceuticals industry average (18x)

Price to Earnings Ratio vs Fair Ratio

What is 1BSL01AE's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1BSL01AE PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio93.5x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 1BSL01AE's Price-To-Earnings Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of 1BSL01AE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 1BSL01AE (€38.6) is trading below our estimate of fair value (€47.23)

Significantly Below Fair Value: 1BSL01AE is trading below fair value, but not by a significant amount.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Future Growth

How is Biotika forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score


Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Biotika has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Discover growth companies

  • Examine Biotika's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.

Past Performance

How has Biotika performed over the past 5 years?

Past Performance Score


Past Performance Score 1/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 1BSL01AE has high quality earnings.

Growing Profit Margin: 1BSL01AE's current net profit margins (4.6%) are lower than last year (12.9%).

Past Earnings Growth Analysis

Earnings Trend: 1BSL01AE's earnings have declined by 1.4% per year over the past 5 years.

Accelerating Growth: 1BSL01AE's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 1BSL01AE had negative earnings growth (-82.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (18.2%).

Return on Equity

High ROE: 1BSL01AE's Return on Equity (1.5%) is considered low.

Discover strong past performing companies

Financial Health

How is Biotika's financial position?

Financial Health Score


Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: 1BSL01AE's short term assets (€9.9M) exceed its short term liabilities (€2.8M).

Long Term Liabilities: 1BSL01AE's short term assets (€9.9M) exceed its long term liabilities (€918.2K).

Debt to Equity History and Analysis

Debt Level: 1BSL01AE has more cash than its total debt.

Reducing Debt: 1BSL01AE's debt to equity ratio has reduced from 29.8% to 0% over the past 5 years.

Debt Coverage: 1BSL01AE's debt is well covered by operating cash flow (51001.1%).

Interest Coverage: 1BSL01AE earns more interest than it pays, so coverage of interest payments is not a concern.

Balance Sheet

Discover healthy companies


What is Biotika current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 1/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage


Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: 1BSL01AE's dividend (6.74%) is higher than the bottom 25% of dividend payers in the SK market (1.13%).

High Dividend: 1BSL01AE's dividend (6.74%) is low compared to the top 25% of dividend payers in the SK market (6.82%).

Stability and Growth of Payments

Stable Dividend: 1BSL01AE has been paying a dividend for less than 10 years and during this time payments have been volatile.

Growing Dividend: 1BSL01AE has only been paying a dividend for 6 years, and since then payments have fallen.

Earnings Payout to Shareholders

Earnings Coverage: With its high payout ratio (448.6%), 1BSL01AE's dividend payments are not well covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: With its high cash payout ratio (6496.4%), 1BSL01AE's dividend payments are not well covered by cash flows.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Biotika has no CEO, or we have no data on them.

Leadership Team

Experienced Management: 1BSL01AE's management team is considered experienced (3.2 years average tenure).

Board Members

Experienced Board: 1BSL01AE's board of directors are considered experienced (4.5 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Company Information

Biotika a.s.'s employee growth, exchange listings and data sources

Key Information

  • Name: Biotika a.s.
  • Ticker: 1BSL01AE
  • Exchange: BSSE
  • Founded: 1953
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: €37.951m
  • Shares outstanding: 983.20k
  • Website:

Number of Employees


  • Biotika a.s.
  • Slovenská Lupca 566
  • Slovenská Lupca
  • 976 13
  • Slovakia


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/10 00:00
End of Day Share Price2022/05/16 00:00
Annual Earnings2021/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.